News Archive

  • VIDO awarded U.S. contract for its Vaccine Development Centre

    VIDO has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract by the United States’ National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

  • VIDO’s first Animal Health Summit brings animal health stakeholders together to prepare for foot and mouth disease

    On August 24th, VIDO hosted a half-day summit on foot-and-mouth disease (FMD). Our biannual Animal Health Summit will bring together stakeholders to facilitate knowledge exchange and preparedness on a topic of interest.

  • VIDO and Pirbright expand collaboration to advance vaccine manufacturing

    VIDO has signed a memorandum of understanding (MOU) with the Centre for Veterinary Vaccine Innovation and Manufacturing at the Pirbright Institute in the UK. The MOU allows for expanded animal health collaborations and training.

  • USask’s VIDO selected for CEPI’s international research network

    VIDO has signed an agreement to join the Coalition for Epidemic Preparedness Innovations’ (CEPI) preclinical research network—the only organization in Canada and the ninth in the world selected for this research network to date.

  • VIDO receives significant CIHR support for research into emerging coronaviruses

    VIDO scientists have received support from the Canadian Institutes of Health Research’s Spring 2023 competition.

  • New funding to advance Canada’s beef sector

    Dr. Antonio Facciuolo has new support to develop a vaccine against Johne’s disease—a chronic intestinal disease of cattle that is significant to both the beef and dairy industry.

  • VIDO scientists strengthen mpox preparedness

    VIDO scientists have received >$1-million in total funding to study mpox (formerly known as monkeypox) from the Canadian Institutes of Health Research “Team Grant: Mpox (monkeypox) and zoonotic threats.”

  • VIDO led technology a key part of the vaccine protecting koalas from chlamydia

    An adjuvant developed by VIDO and partners is a key component in a vaccine to protect koalas from chlamydia. The adjuvant improves the effectiveness of the vaccine by improving the koala immune response.

  • VIDO and VFI collaborate to strengthen pandemic preparedness

    VIDO and the Vaccine Formulation Institute (VFI) sign collaborative research agreement to help drive joint vaccine development and support a rapid and unified response to future pandemics.

  • VIDO scientists receive leadership awards for excellence in vaccine research

    Drs. Darryl Falzarano and Alyson Kelvin have been recognized by the Canadian Institutes of Health Research (CIHR) for their international leadership in vaccine research for infectious diseases.